Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Denmark Germany Hungary Italy The Netherlands +3
  • A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn’s disease or ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    Austria Belgium Bulgaria Croatia Czechia France +8
  • A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Finland France Germany Italy Poland Slovakia
  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Croatia France Germany Greece Hungary +5
  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    Austria Belgium Bulgaria Croatia Czechia France +10
  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    Belgium Czechia France Germany Greece Hungary +7
  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Belgium Bulgaria Croatia Czechia Germany Italy +2
  • Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Hungary Poland Spain
  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Germany Greece Italy Spain Sweden
  • Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Bulgaria Denmark Ireland Italy The Netherlands +4